News

Beckman Coulter launches diagnostics system

Beckman Coulter Diagnostics will be showcasing its new DxN VERIS Molecular Diagnostics System at ECCMID 2015 in Copenhagen.

Photo: Beckman Coulter launches diagnostics system

The CE-marked system is now available with CE-marked assays for Human Cytomegalovirus (CMV) and Hepatitis B Virus (HBV)*. Additional assays for Human Immunodeficiency Virus (HIV-1) and Hepatitis C Virus (HCV) have been submitted for CE-mark certification*. Further menu expansion will follow with many other assays currently in development.

“The DxN VERIS Molecular Diagnostics System is designed to revolutionise the clinical laboratory with LEAN workflow and improved sample turn-around time,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “The system’s true single sample random access empowers laboratories to perform viral load tests whenever they want, at a time that suits them—ultimately helping physicians make faster clinical decisions and positively impacting patients.”

The DxN VERIS Molecular Diagnostics System assays are supplied in a unique, single cartridge system that are cost- and time-effective. Unlike traditional batch-plate systems, there are no empty wells, so the DxN VERIS Molecular Diagnostics System reduces wastage and consumable costs. With the DxN VERIS Molecular Diagnostics System, all necessary consumables and reagents are on-board, so there is no lengthy set-up and tests can be up and running in less than 10 minutes.

“With rapid processing, the DxN VERIS Molecular Diagnostics System’s short run-times ensure that results are delivered to physicians as quickly as possible,” Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics. “By consolidating DNA extraction, amplification and detection within a single instrument, we have significantly reduced manual intervention and are enabling labs to go from a sample to an answer in just 70 minutes.”

24.04.2015

More on the subject:More on companies:
Read all latest stories

Related articles

Photo

High-sensitivity troponin I assay

Speeding up diagnosis of myocardial infarction

The new generation troponin I assay unveiled by Beckman Coulter is helping improve heart attack diagnosis. Delivering high sensitivity, and rapid result turnaround times, every element of the Access…

Photo

Blood poisoning

Exploring the importance and challenges of early sepsis diagnosis

On the occasion of this year's World Sepsis Day, we spoke with Elena Sukhacheva, Ph.D., director of medical and scientific affairs at Beckman Coulter, about the status quo and outlook on sepsis…

Photo

Hematology

Early sepsis indicator helps identifying patients at risk

The critical element of testing for sepsis lies not so much in the location but in the timing and rapidity of results, according to Professor Jeannine T. Holden from Beckman Coulter Early…

Related products

Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter, Inc.
Beckman Coulter – Access Interleukin-6 (IL-6)

Immunoassays

Beckman Coulter – Access Interleukin-6 (IL-6)

Beckman Coulter, Inc.
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter, Inc.
Beckman Coulter – AU5800 Series

Clinical Chemistry

Beckman Coulter – AU5800 Series

Beckman Coulter, Inc.
Beckman Coulter – DxA 5000

Sample Processing

Beckman Coulter – DxA 5000

Beckman Coulter, Inc.